Is it true that Zolbetuximab-Vyloy is so effective?

Zolbetuximab (Zolbetuximab)-Vyloy is an innovative targeted antibody drug mainly used to treat Claudin 18.2-positive gastric cancer and gastroesophageal junction adenocarcinoma (GEJ adenocarcinoma). As a new type of anti-cancer drug, the therapeutic effect of zotuximab has shown significant advantages in clinical trials, especially when used in combination with traditional chemotherapy, and is therefore considered by many to be a new hope for gastric cancer treatment. However, patients and the public are often skeptical about the effectiveness of drugs, especially drugs with high therapeutic expectations like zotuximab. So, does zotuximab really work as advertised?

The mechanism of action of zotuximab is very unique. It selectively eliminates tumor cells by targeting the Claudin 18.2 protein on the surface of cancer cells. At the same time, it can enhance the anti-tumor effect when used in combination with chemotherapy drugs. Studies have shown that for patients with Claudin 18.2-positive gastric cancer, zotuximab can significantly improve the patient's treatment response rate, prolong progression-free survival (PFS) and overall survival (OS). In some clinical trials, combination treatment regimens with zotuximab have shown better results in relieving tumors than traditional chemotherapy drugs. Especially in patients with advanced and metastatic gastric cancer, the use of zotuximab has significantly improved treatment outcomes.

However, despite encouraging clinical results, zotuximab is not a panacea. First of all, zotuximab is only suitable for patients with Claudin 18.2-positive gastric cancer and must be used in combination with chemotherapy regimens containing fluoropyrimidine and platinum. For patients who are Claudin 18.2 negative, the effect of zotuximab may be greatly reduced. Therefore, patients need to pass relevant biomarker testing before use to confirm whether they are suitable for using this drug. In addition, as a targeted drug, zotuximab has relatively mild side effects, but common adverse reactions such as nausea, vomiting, and fatigue may still occur. Patients need to use it under the guidance of a doctor and regularly monitor relevant physiological indicators.

In addition, the effect of a drug is often closely related to individual differences among patients, the severity of the condition, and whether it is used in combination with other drugs. Not every patient will benefit from zotuximab, especially those with advanced disease or who have developed multiple resistance mechanisms. Therefore, while zotuximab has shown promising efficacy in some clinical trials, it may not be the most appropriate treatment option for some patients.

In general, zotuximab is indeed a drug with significant efficacy, especially in Among Claudin 18.2-positive gastric cancer patients, the combination chemotherapy regimen can improve the treatment response rate and survival to a certain extent. However, whether patients can benefit from it still needs to be comprehensively considered based on the individual's specific condition and drug indications. Therefore, we can have a positive but cautious attitude towards the effect of zotuximab and make scientific treatment decisions under the guidance of doctors.

Reference: https://newsroom.astellas.us/2024-10-18-Astellas-VYLOY-TM-zolbetuximab-clzb-Approved-by-U-S-FDA-for-Treatment-of-Advanced-Gastric-and-GEJ-Cancer